Sagimet Biosciences Highlights Progress Despite Rising Losses and Operating Costs in Q1 2025

Sagimet Biosciences Inc. (NASDAQ: SGMT) has recently reported its financial results for the quarter ended March 31, 2025. The company remains in the clinical stage of developing its lead product, denifanstat, a novel fatty acid synthase (FASN) inhibitor targeting conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and acne.

Positive Aspects:

• Denifanstat has received Breakthrough Therapy designation from the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis.
• The Phase 2b FASCINATE-2 trial produced statistically significant results in primary and secondary endpoints.
• As of March 31, 2025, Sagimet had cash, cash equivalents, and marketable securities totaling $144.6 million, indicating significant resources to fund ongoing development.
• The company completed a follow-on offering in January 2024, raising $104.7 million in net proceeds, enhancing financial stability.

Negative Aspects:

• Net loss for Q1 2025 was $18.2 million, up from $6.6 million in Q1 2024, representing a 174% increase.
• Operating expenses grew substantially by 127% to $19.9 million, primarily due to increased research and development costs.
• The company reported cash used in operating activities at $14.5 million for Q1 2025, indicating ongoing negative cash flow.
• Total liabilities increased compared to previous reporting periods, reflecting the need for continued funding.

Key Statistics:

• Q1 2025 Research and Development Expenses: $15.3 million (192% increase year-over-year)
• General and Administrative Expenses: $4.5 million (29% increase year-over-year)
• Weighted Average Shares Outstanding: 32,195,345
• Net Loss per Share: $0.56 compared to $0.23 in Q1 2024
• Cash and Cash Equivalents on March 31, 2025: $64.7 million

Sagimet is poised for extensive clinical development and has strategic partnerships that bolster its R&D efforts, though it faces challenges with rising costs and considerable losses. The company continues to explore funding options to support its clinical trials and operational needs as it seeks to advance its innovative treatment offerings in the biopharmaceutical market.